Understanding the Difference Between Chemo and Immunotherapies with Dr. Scott Goldsmith

Name: Understanding the Difference Between Chemo and Immunotherapies with Dr. Scott Goldsmith
Start: 2022-04-27T13:00:00-04:00
End: 2022-04-27T14:00:00-04:00

Understanding the Difference Between Chemo and Immunotherapies with Dr. Scott Goldsmith

Newly Diagnosed Myeloma

Apr 27, 2022 / 01:00PM - 02:00PM EDT

Event Description

Join Dr. Scott Goldsmith, myeloma specialist from City of Hope, as he shares with us the difference between chemotherapy and immunotherapy in myeloma treatments.

What drugs constitute as Immunotherapy? What is the difference in mechanism of action? Which are more effective in treating myeloma?
Come with your questions and get ready to learn with us.

Schedule & Agenda

Introduction

01:00PM

Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr. Scott Goldsmith

01:00PM

Audrey Burton-Bethke

Introduction

Audrey introduces the agenda of the event and featured speaker Dr. Scott Goldsmith

Presentation

01:05PM

Dr. Scott Goldsmith

Dr. Goldsmith shares with us the difference between chemotherapy and immunotherapy in myeloma treatments.

01:05PM

Dr. Scott Goldsmith

Presentation

Dr. Goldsmith shares with us the difference between chemotherapy and immunotherapy in myeloma treatments.

Questions and Answers

01:35PM

Audience

Type your questions in the chat and we will answer them!

01:35PM

Audience

Questions and Answers

Type your questions in the chat and we will answer them!

Speakers & Moderators

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio

Scott Goldsmith, MD

Scott R. Goldsmith MD specializes in the treatment of multiple myeloma, which is also the focus of his prolific research. “I am passionate about bringing new and innovative treatments to patients with multiple myeloma and other hematologic malignancies through translational research and clinical trials,” he said.

Read Bio